|The CCL-5 ccl5 (Catalog #MBS690374) is an Antibody produced from Rat and is intended for research purposes only. The product is available for immediate purchase. The Rat Anti-Mouse CCL-5 reacts with Mouse and may cross-react with other species as described in the data sheet. MyBioSource\'s CCL-5 can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA), Immunohistochemistry (IHC) - Formalin, Neutr. Researchers should empirically determine the suitability of the CCL-5 ccl5 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The CCL-5 ccl5 product has the following accession number(s) (GI #164698428) (NCBI Accession #NP_038681.2) (Uniprot Accession #P30882). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
CCL5, also known as RANTES (Regulated upon Activation, Normal T cell Expressed and presumably Secreted), is an 8 kDa betachemokine that plays a primary role in the inflammatory immune response by means of its ability to attract and activate leukocytes. Human and mouse RANTES exhibit cross-species activity on human and mouse cells (4). Mature mouse CCL5 shares 100% amino acid (aa) sequence identity with rat CCL5 and 75-88% with canine, cotton rat, feline, and human CCL5. CCL5 is secreted by many cell types at inflammatory sites, and it exerts a wide range of activities through the receptors CCR1, CCR3, CCR4, and CCR5. Inflammatory responses can be impaired by the sequestration of CCL5 by the cytomegalovirus protein US28. In humans, CCR5 binding to CCL5 inhibits the infectivity of R5 (M tropic) but not X4 (T tropic) strains of HIV. The two N-terminal residues of CCL5 can be removed by CD26/DPPIV, generating a protein that functions as a chemotaxis inhibitor and more effectively blocks M tropic HIV 1 infection of monocytes. Oligomerization of CCL5 on glycosaminoglycans is required for CCR1mediated leukocyte adhesion and activation as well as CCL5\'s interaction with the chemokine CXCL4/PF4. The deposition of CCL5 on activated vascular endothelial cells is crucial for monocyte adhesion to damaged vasculature, but CCL5 oligomerization is not required for the extravasation of adherent leukocytes. CCL5 is upregulated in breast cancer and promotes tumor progression through the attraction of proinflammatory macrophages in addition to its actions on tumor cells, stromal cells, and the vasculature.
Reconstitution: Reconstitute the antibody with 200 ul sterile PBS and the final concentration is 500 ug/ml. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing CCL-5 are readily searchable from our website. Different antibodies against the same target such as CCL-5 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.